Evidence map›Paper›PMID 28404355›Full record

ArticleVaccine2017

Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines.

G Thomas Ray, Ned Lewis, Kristin Goddard, Pat Ross, Jonathan Duffy, Frank DeStefano, Roger Baxter, Nicola P Klein

Abstract readComparative Study
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Asthma.Pediatrics in review · 2019
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

G Thomas RayKaiser Permanente Vaccine Study Center and Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, Oakland, CA, United States. Electronic address: tom.ray@kp.org.
Ned LewisKaiser Permanente Vaccine Study Center and Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, Oakland, CA, United States.
Kristin GoddardKaiser Permanente Vaccine Study Center and Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, Oakland, CA, United States.
Pat RossKaiser Permanente Vaccine Study Center and Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, Oakland, CA, United States.
Jonathan DuffyImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Frank DeStefanoImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Roger BaxterKaiser Permanente Vaccine Study Center and Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, Oakland, CA, United States.
Nicola P KleinKaiser Permanente Vaccine Study Center and Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, Oakland, CA, United States.
Kaiser Permanente · USCenters for Disease Control and Prevention · USNational Center for Immunization and Respiratory Diseases · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

objectiveTo investigate whether there is a difference in the risk of asthma exacerbations between children with pre-existing asthma who receive live attenuated influenza vaccine (LAIV) compared with inactivated influenza vaccine (IIV). MATERIAL AND

methodsWe identified IIV and LAIV immunizations occurring between July 1, 2007 and March 31, 2014 among Kaiser Permanente Northern California members aged 2 to <18years with a history of asthma, and subsequent asthma exacerbations seen in the inpatient or Emergency Department (ED) setting. We calculated the ratio of the odds (OR) of an exacerbation being in the risk interval (1-14days) versus the comparison interval (29-42days) following immunization, separately for LAIV and IIV, and then examined whether the OR differed between children receiving LAIV and those receiving IIV ("difference-in-differences").

resultsAmong 387,633 immunizations, 85% were IIV and 15% were LAIV. Children getting LAIV vs. IIV were less likely to have "current or recent, persistent" asthma (25% vs. 47%), and more likely to have "remote history" of asthma (47% vs. 25%). Among IIV-vaccinated asthmatic children, the OR of an inpatient/ED asthma exacerbation was 0.97 (95% CI: 0.82-1.15). Among LAIV-vaccinated asthmatic children the OR was 0.38 (95% CI: 0.17-0.90). In the difference-in-differences analysis, the odds of asthma exacerbation following LAIV were less than IIV (Ratio of ORs: 0.40, CI: 0.17-0.95, p value: 0.04).

conclusionAmong children ≥2years old with asthma, we found no increased risk of asthma exacerbation following LAIV or IIV, and a decreased risk following LAIV compared to IIV.

Indexed as

AdolescentAsthmaCaliforniaChildChild, PreschoolDrug-Related Side Effects and Adverse ReactionsFemaleHumansInfluenza, HumanInfluenza VaccinesMaleStatus AsthmaticusVaccines, AttenuatedVaccines, InactivatedInfluenza VaccinesVaccines, AttenuatedVaccines, InactivatedAsthmaInfluenzaSafetyVaccines

Identifiers

PMID28404355
PMCPMC6636629
OpenAlexW2606363712

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.